The Expanding Armamentarium for EGFR-Mutated Metastatic NSCLC
Exclusive
•
1h 3m
Explore the expanding treatment options for EGFR mutated metastatic non-small cell lung cancer. Key topics include the role of biomarkers in treatment decisions, FDA-approved targeted therapies, and the necessity of comprehensive testing. A case study illustrates the diagnostic process leading to the identification of an EGFR Exon 19 deletion. The session emphasizes the importance of tailored treatment approaches and collaboration among healthcare professionals to improve patient outcomes.
Up Next in Exclusive
-
ARC TALKS Webinar: Clinical Trial Upd...
The video is a webinar titled “ARC TALKS Webinar: Clinical Trial Updates for the ATTR Community,” presented by Kristen Hsu, ARC’s Executive Director of Research. The presentation is designed to update the ATTR amyloidosis community on the evolving clinical trial landscape for treatments targeting...
-
Advancing the Myelofibrosis Treatment...
Assess the pathogenesis and progression of myelofibrosis, including underlying pathophysiologic mechanisms and the most frequently related primary mutations
Examine the patient burden of myelofibrosis, reviewing its prevalence, clinical manifestations, and evidence-supported risk stratification a... -
JMIR Medical Education How does ChatG...
